Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma

Bevacizumab and cetuximab both improve treatment efficacy when administered with chemotherapy for metastatic colorectal carcinoma (mCRC). Cetuximab has enhanced efficacy in Kras wild-type tumors. However, inferior outcomes have been demonstrated concerning the concurrent use of bevacizumab and cetux...

Descripción completa

Detalles Bibliográficos
Autores principales: LAM, KA ON, LEE, VICTOR HO FUN, LIU, RICO KIN YIN, LEUNG, TO WAI, KWONG, DORA LAI WAN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2013
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573099/
https://www.ncbi.nlm.nih.gov/pubmed/23420587
http://dx.doi.org/10.3892/ol.2012.1045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573099/
https://www.ncbi.nlm.nih.gov/pubmed/23420587
http://dx.doi.org/10.3892/ol.2012.1045

Ejemplares similares